Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -22.94

Pulse Biosciences, Inc. Price to Earnings Ratio (P/E) is -22.94 on January 14, 2025, a -114.04% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Pulse Biosciences, Inc. 52-week high Price to Earnings Ratio (P/E) is -8.74 on April 25, 2024, which is 61.90% above the current Price to Earnings Ratio (P/E).
Pulse Biosciences, Inc. 52-week low Price to Earnings Ratio (P/E) is -29.64 on December 04, 2024, which is -29.21% below the current Price to Earnings Ratio (P/E).
Pulse Biosciences, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -17.85.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years